Effect of I-PRF Application on ALP and MMP-9 Levels in Teeth With Apical Periodontitis
The Effect of Injectable Platelet-Rich Fibrin on Alkaline Phosphatase and Matrix Metalloproteinase-9 Levels in Periapical Exudate and Gingival Crevicular Fluid of Teeth With Apical Periodontitis
1 other identifier
observational
60
1 country
1
Brief Summary
The aim of this study was to evaluate the effect of injectable platelet rich fibrin (i-PRF) injection, in addition to routine root canal treatment, on alkaline phosphatase (ALP) and matrix metalloproteinase-9 (MMP-9) levels in teeth with chronic apical periodontitis. A total of 60 patients were included and randomly divided into two groups: the control group and the experimental group (i-PRF). Gingival crevicular fluid (GCF) samples and periapical exudate (PAE) samples were collected from the teeth at the first appointment, after completion of chemomechanical preparation. In both groups, calcium hydroxide was placed in the root canals, and the teeth were temporarily sealed with composite resin. While no additional procedure was performed in the control group, patients in the experimental group received submucosal i-PRF injection. The second samples were obtained after 4 weeks, and in the same session, the root canal treatment was completed, followed by permanent restoration. ALP and MMP-9 levels in the collected samples were analyzed using the ELISA test.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 10, 2025
CompletedFirst Submitted
Initial submission to the registry
November 27, 2025
CompletedFirst Posted
Study publicly available on registry
January 6, 2026
CompletedMarch 31, 2026
March 1, 2026
5 months
November 27, 2025
March 25, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
ALP and MMP-9 Levels in Periapical Exudate (PAE) and Gingival Crevicular Fluid (GCF)
In teeth with apical periodontitis, periapical exudate (PAE) and gingival crevicular fluid (GCF) collected during the first and second sessions of root canal treatment will be analyzed to measure alkaline phosphatase (ALP) and matrix metalloproteinase-9 (MMP-9) levels. ALP levels will be expressed in U/L, while MMP-9 levels will be expressed in ng/dL, and each enzyme will be measured and reported separately. Enzyme levels will be compared between the group receiving injectable platelet-rich fibrin (i-PRF) and the group not receiving i-PRF.
Baseline and 28. Days
Secondary Outcomes (1)
Comparison of ALP and MMP-9 Levels Between Sessions and Sample Types
Baseline and 28. Days
Study Arms (2)
Control Group
30 participants. Procedure: Root canal treatment without i-PRF application. Collection of GCF and PAE samples.
I-PRF Group
30 participants. Procedure: i-PRF application and root canal treatment. Collection of GCF and PAE samples.
Eligibility Criteria
Patients between the ages of 18-64 years old and diagnosed with apical periodontitis who applied to Kırıkkale University, Faculty of Dentistry, Department of Endodontics with the indication of root canal treatment will be included in the study.
You may qualify if:
- Sixty patients who applied to Kırıkkale University Faculty of Dentistry and were diagnosed with chronic apical periodontitis and were included in the PAI 3-4 groups according to the Periapical Index Scoring System (PAI) among the patients who were prescribed root canal treatment were included in the study.
- Patients aged 18-64
- Upper or lower incisors and premolars with primary apical periodontitis
- Patients with ASA I
- Patients who have provided written informed consent to participate in the study.
You may not qualify if:
- Patients with ASA II or higher,
- Patients who have used antibiotics and anti-inflammatory medications within the last month,
- Patients with a periodontal pocket greater than 3 mm in the affected tooth,
- Teeth with internal or external root resorption, or teeth with swelling and pain on palpation,
- Pregnant women or those suspected of pregnancy,
- Patients with generalized periodontitis,
- Patients with immunosuppressive systemic diseases such as diabetes and hepatitis will not be included in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kırıkkale University, Faculty of Dentistry
Kırıkkale, Kırıkkale, 71100, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gamze E NALBANT, Research Assistant
Kirikkale University Faculty of Dentistry
- STUDY CHAIR
Ali Türkyılmaz, Associate Professor
Kirikkale University Faculty of Dentistry
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
November 27, 2025
First Posted
January 6, 2026
Study Start
January 1, 2025
Primary Completion
June 1, 2025
Study Completion
October 10, 2025
Last Updated
March 31, 2026
Record last verified: 2026-03